Luspatercept for CIA in AML

This study aims to explore the feasibility, safety, and preliminary efficacy of rotegcipipone in the treatment of chemotherapy-inducing anemia in AML with a multicenter, prospective, single-arm trial, providing clinical evidence for subsequent clinical development.

Trial Details

NCT ID
NCT07663864
Phase
PHASE1 / PHASE2
Sponsor
Guangdong Second Provincial General Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Luspatercept Injectable Product
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • De novo AML patients;
  • Age ≥ 18 years and ≤ 60 years;
  • AML with ELN2022-low risk
  • Received 1-3 cycles of HDAC consolidation therapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →